Boehringer Ingelheim Fremont, Inc
6701 Kaiser Drive
869 articles with Boehringer Ingelheim Fremont, Inc
Calculus Capital, the award-winning Enterprise Investment Scheme (EIS) and Venture Capital Trust (VCT) specialist, has invested £2m in Oxford BioTherapeutics (OBT), a clinical-stage oncology company that is developing next-generation cancer treatments.
Boehringer Ingelheim Demonstrates Their Commitment to Site Relationships by Joining SCRS’ Global Impact Partner Program
Becoming a GIP demonstrates the company’s commitment to clinical research sites and their desire to develop a deeper understanding of the needs of sites, and contribute to the development and implementation of solutions.
Another potential treatment for Alzheimer's disease has been tossed into the rubbish bin.
Merial, Now Part of Boehringer Ingelheim, Grows Canine Vaccine Portfolio With Introduction of RECOMBITEK Oral Bordetella
RECOMBITEK vaccines are manufactured by Merial. Merial is now a part of Boehringer Ingelheim.
Boehringer Ingelheim Announces Paul Fonteyne to Retire at the end of 2018. Wolfgang Baiker Appointed U.S. President & CEO Effective March 1, 2018.
Boehringer Ingelheim announced today that Paul Fonteyne, U.S. President and CEO will retire after 15 years of committed service on December 31, 2018.
As a PBM owned by 18 Blue Cross and Blue Shield plans, Prime is uniquely positioned to analyze both medical and pharmacy claims data to evaluate and manage total cost of care.
New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment
The study examined major bleeding and stroke rates in NVAF patients who had initiated treatment with Pradaxa compared to those treated with rivaroxaban or apixaban.
Boehringer Ingelheim Release: Respimat Inhaler Awarded Arthritis Foundation’s Ease of Use Commendation
Boehringer Ingelheim announced today that the Arthritis Foundation recognized Respimat with its Ease of Use Commendation.
BeiGene and Boehringer Ingelheim Announce Commercial Supply Agreement for Anti-PD-1 Antibody Tislelizumab
Tislelizumab will be manufactured in Boehringer Ingelheim’s world-class biopharmaceutical manufacturing facility in Shanghai.
Boehringer Ingelheim Release: New Documentary Film Shines Light on Physical and Emotional Impact of COPD
The film was created by Emmy-nominated director Abbey LeVine in collaboration with Boehringer Ingelheim Pharmaceuticals.
The collaboration is part of Boehringer Ingelheim's RBB initiative that explores emerging science and technologies for and beyond its core therapeutic areas to create new opportunities in disease indications of high medical need.
Together, Boehringer Ingelheim and Roche will leverage complementary expertise and innovative LNA technology to bring novel treatment approaches to IBD patients.
Boehringer Ingelheim Release: FDA Grants Priority Review To Gilotrif For Uncommon EGFR Mutations In Advanced NSCLC
Anthem, HealthCore And Boehringer Ingelheim Initiate World’s Largest Pragmatic Clinical Trial To Study People Living With COPD In A Real-World Setting
Siamab And Boehringer Ingelheim Announce Strategic Cancer Immunology Discovery Collaboration To Develop Antibody Therapeutics Targeting Multiple Solid Tumors
Boehringer Ingelheim Partners With Greatergood.Org; Provides Over Half A Million Dollars In Product Aid To Pets Affected By Hurricanes Harvey And Irma
ImaginAb, Inc. Announces Strategic Collaboration With Boehringer Ingelheim To Develop New Technology For Monitoring Anti-Tumor Activity Of The Immune System
Geisinger And Boehringer Ingelheim Collaborate To Create A Predictive Model To Help Improve Health Outcomes For People With Type 2 Diabetes At Greatest Risk Of Serious Long-Term Complications, Including Cardiovascular Death
Boehringer Ingelheim Release: New Documentary Film Shines Light On Physical And Emotional Impact Of COPD